As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to：www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global：
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China：
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Jan 29th, 2021 – CDE announced that the innovative drug, 3D011-08 from 3D Medicines, was approved of conducting clinical trials. It indicates that 3D Medicines has the capacity to develop innovative drugs with global intellectual property rights, which has laid a solid foundation for the achievement of the company’s long-term sustainable development strategic goals. 3D011 is a class I innovative drug for the treatment of advanced solid tumors.
Medicilon's preparation laboratory and workshop area is about 4,000 square meters, with 100 professional R&D teams, of which more than 40% are masters/doctors, and more than 95% are undergraduates. The team has rich experience in successful research and development of innovative drugs, consistency evaluation, and improved new drugs, and experience in China-US dual filing and project management. The Medicilon pharmaceutical preparation R&D team has successfully cooperated with well-known large and medium-sized pharmaceutical companies worldwide, and has accumulated 18 years of experience in the research and application of innovative drugs and generic drugs. We provide one-stop and systematic preparation R&D services covering innovative drugs and generic drugs to meet the needs of customers at different stages of R&D.
Medicilon assists HitGen's HG381 to be approved as China's first clinical STING agonist
Guangzhou Magpie Pharmaceuticals was approved by NMPA to start the clinical trials of MN-08 with the help of Medicilon
Assisting the development of the Chinese new anti-influenza drug ADC189 preparation, Medicilon and AnDiCon Bio reached a collaboration
Share：
Relevant
news
marketing@medicilon.com
ABOUT
